ELEDON PHARMACEUTICALS INC (ELDN) — insider trading
Health Care · NASDAQ
ELEDON PHARMACEUTICALS INC (ELDN) has 28 reported SEC Form 4 insider transactions in our data (latest 2026-07-31).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | Perrin Steven | Director, Officer (President) | Shares withheld for taxes / exercise cost | 72,138 | $3.38 | $243.8K | Form 4 |
| 2026-07-31 | Perrin Steven | Director, Officer (President) | Grant / award / vesting | 152,353 | — | $0 | Form 4 |
| 2026-07-31 | Gros David-Alexandre C | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 194,791 | $3.38 | $658.4K | Form 4 |
| 2026-07-31 | Gros David-Alexandre C | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 354,454 | — | $0 | Form 4 |
| 2026-01-10 | Robinson James A. Jr. | Director | Option exercise / conversion (derivative) | 3,430 | — | $0 | Form 4 |
| 2026-01-10 | Robinson James A. Jr. | Director | Option exercise / conversion | 3,430 | — | $0 | Form 4 |
| 2026-01-10 | Lee June | Director | Option exercise / conversion (derivative) | 3,430 | — | $0 | Form 4 |
| 2026-01-10 | Lee June | Director | Option exercise / conversion | 3,430 | — | $0 | Form 4 |
| 2026-01-10 | Katkin Keith | Director | Option exercise / conversion (derivative) | 8,575 | — | $0 | Form 4 |
| 2026-01-10 | Katkin Keith | Director | Option exercise / conversion | 8,575 | — | $0 | Form 4 |
| 2026-01-10 | Kirk Allan | Director | Option exercise / conversion (derivative) | 3,430 | — | $0 | Form 4 |
| 2026-01-10 | Kirk Allan | Director | Option exercise / conversion | 3,430 | — | $0 | Form 4 |
| 2026-01-10 | Hillson Jan | Director | Option exercise / conversion (derivative) | 3,430 | — | $0 | Form 4 |
| 2026-01-10 | Hillson Jan | Director | Option exercise / conversion | 3,430 | — | $0 | Form 4 |
| 2026-01-10 | McBride John S. | Director | Option exercise / conversion (derivative) | 3,430 | — | $0 | Form 4 |
| 2026-01-10 | McBride John S. | Director | Option exercise / conversion | 3,430 | — | $0 | Form 4 |
| 2025-01-10 | Smith Bryan E. | Officer (General Counsel, Corporate Sec) | Grant / award / vesting (derivative) | 64,500 | — | $0 | Form 4 |
| 2025-01-10 | Smith Bryan E. | Officer (General Counsel, Corporate Sec) | Grant / award / vesting (derivative) | 150,500 | — | $0 | Form 4 |
| 2025-01-10 | Katkin Keith | Director | Grant / award / vesting (derivative) | 8,575 | — | $0 | Form 4 |
| 2025-01-10 | Katkin Keith | Director | Grant / award / vesting (derivative) | 77,175 | — | $0 | Form 4 |
| 2025-01-10 | Little Paul Sean | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 75,000 | — | $0 | Form 4 |
| 2025-01-10 | Little Paul Sean | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 175,000 | — | $0 | Form 4 |
| 2025-01-10 | Gros David-Alexandre C | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 66,500 | — | $0 | Form 4 |
| 2025-01-10 | Gros David-Alexandre C | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 600,000 | — | $0 | Form 4 |
| 2025-01-10 | McBride John S. | Director | Grant / award / vesting (derivative) | 3,430 | — | $0 | Form 4 |
| 2025-01-10 | McBride John S. | Director | Grant / award / vesting (derivative) | 30,870 | — | $0 | Form 4 |
| 2025-01-10 | Hillson Jan | Director | Grant / award / vesting (derivative) | 3,430 | — | $0 | Form 4 |
| 2025-01-10 | Hillson Jan | Director | Grant / award / vesting (derivative) | 30,870 | — | $0 | Form 4 |
Ask the chat about ELDN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ELEDON PHARMACEUTICALS INC (ELDN).
Last updated 2026-07-31 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.